UPDATE: Morgan Stanley Initiates Seattle Genetics With Equal-Weight, $123 Target Notes '2019 has been a pivotal year with upside data on the pipeline beyond lead asset Adcetris'; Equal-Weight, $123 Target Reflects 'current high expectations'